BACKGROUND: The current study was conducted to evaluate the patterns of care and survival of older adults with oligodendroglioma (OLI) and astrocytoma (AST) from a large population-based registry. METHODS: The authors identified a cohort of OLI and AST patients aged >or=65 years from Surveillance, Epidemiology and End Results (SEER) cancer registry data linked with Medicare claims between 1994 and 2002. Patients with a diagnosis of glioblastoma were excluded. The impact of demographic characteristics and comorbidities on the probability of undergoing surgical resection, radiotherapy (RT), and chemotherapy within 6 months of diagnosis was assessed using multivariate logistic regression. RESULTS: A total of 1067 patients (891 with AST and 176 with OLI) were included; the median survival was 9 months for patients with low-grade AST, 4 months for patients with anaplastic AST, 57 months for patients with low-grade OLI, and 9 months for patients with anaplastic OLI. Approximately 54% of patients underwent resection at the time of diagnosis; 66% received RT, and 13% received chemotherapy within 6 months of diagnosis. In a multivariate regression analysis, age and tumor grade were found to be the most significant predictors of resection, RT, or chemotherapy. Patients with anaplastic tumors were treated with resection, RT, and chemotherapy more often than patients with low-grade tumors, and OLI patients received chemotherapy more frequently than AST. CONCLUSIONS: Data from the current study suggested that histologic diagnosis and tumor grade retained significant prognostic value in this elderly AST and OLI population. Furthermore, age and tumor grade were found to influence the probability of undergoing surgery, RT, and chemotherapy in this cohort. (c) 2009 American Cancer Society.
BACKGROUND: The current study was conducted to evaluate the patterns of care and survival of older adults with oligodendroglioma (OLI) and astrocytoma (AST) from a large population-based registry. METHODS: The authors identified a cohort of OLI and AST patients aged >or=65 years from Surveillance, Epidemiology and End Results (SEER) cancer registry data linked with Medicare claims between 1994 and 2002. Patients with a diagnosis of glioblastoma were excluded. The impact of demographic characteristics and comorbidities on the probability of undergoing surgical resection, radiotherapy (RT), and chemotherapy within 6 months of diagnosis was assessed using multivariate logistic regression. RESULTS: A total of 1067 patients (891 with AST and 176 with OLI) were included; the median survival was 9 months for patients with low-grade AST, 4 months for patients with anaplastic AST, 57 months for patients with low-grade OLI, and 9 months for patients with anaplastic OLI. Approximately 54% of patients underwent resection at the time of diagnosis; 66% received RT, and 13% received chemotherapy within 6 months of diagnosis. In a multivariate regression analysis, age and tumor grade were found to be the most significant predictors of resection, RT, or chemotherapy. Patients with anaplastic tumors were treated with resection, RT, and chemotherapy more often than patients with low-grade tumors, and OLI patients received chemotherapy more frequently than AST. CONCLUSIONS: Data from the current study suggested that histologic diagnosis and tumor grade retained significant prognostic value in this elderly AST and OLI population. Furthermore, age and tumor grade were found to influence the probability of undergoing surgery, RT, and chemotherapy in this cohort. (c) 2009 American Cancer Society.
Authors: M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim Journal: Lancet Date: 2005 Sep 17-23 Impact factor: 79.321
Authors: Lauren E Abrey; David N Louis; Nina Paleologos; Andrew B Lassman; Jeffrey J Raizer; Warren Mason; Jonathan Finlay; David R MacDonald; Lisa M DeAngelis; J Gregory Cairncross Journal: Neuro Oncol Date: 2007-04-13 Impact factor: 12.300
Authors: Margaret Wrensch; Terri Rice; Rei Miike; Alex McMillan; Kathleen R Lamborn; Kenneth Aldape; Michael D Prados Journal: Neuro Oncol Date: 2006-01 Impact factor: 12.300
Authors: Nader Pouratian; Melike Mut; Jay Jagannathan; M Beatriz Lopes; Mark E Shaffrey; David Schiff Journal: J Neurooncol Date: 2008-08-06 Impact factor: 4.130
Authors: J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506
Authors: Kaisorn L Chaichana; Hasan Zaidi; Courtney Pendleton; Matthew J McGirt; Rachel Grossman; Jon D Weingart; Alessandro Olivi; Alfredo Quiñones-Hinojosa; Henry Brem Journal: Neurol Res Date: 2011-09 Impact factor: 2.448
Authors: Shota Tanaka; Fredric B Meyer; Jan C Buckner; Joon H Uhm; Elizabeth S Yan; Ian F Parney Journal: J Neurooncol Date: 2012-08-09 Impact factor: 4.130
Authors: Kaisorn L Chaichana; Khan K Chaichana; Alessandro Olivi; Jon D Weingart; Richard Bennett; Henry Brem; Alfredo Quiñones-Hinojosa Journal: J Neurosurg Date: 2010-10-01 Impact factor: 5.115
Authors: Kaisorn L Chaichana; Tomas Garzon-Muvdi; Scott Parker; Jon D Weingart; Alessandro Olivi; Richard Bennett; Henry Brem; Alfredo Quiñones-Hinojosa Journal: Ann Surg Oncol Date: 2010-08-10 Impact factor: 5.344
Authors: Jacob S Young; Steven J Chmura; Derek A Wainwright; Bakhtiar Yamini; Katherine B Peters; Rimas V Lukas Journal: J Neurol Sci Date: 2017-08-01 Impact factor: 3.181